Exelixis Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. Its lead product, CABOMETYX tablets (cabozantinib), treats advanced renal cell carcinoma in patients following prior anti-angiogenic therapy and supports expansion into indications like neuroendocrine tumors. COMETRIQ capsules (cabozantinib) address progressive, metastatic medullary thyroid cancer. The company also markets COTELLIC (cobimetinib) and advances a pipeline including zanzalintinib, evaluated in trials such as STELLAR-303 for metastatic colorectal cancer in combination with immune checkpoint inhibitors. Exelixis leverages expertise in chemistry, biology, and strategic partnerships to develop small molecules, bispecific antibodies, antibody-drug conjugates, and other innovative anti-cancer therapies. These efforts target tyrosine kinases like MET, AXL, RET, and VEGF receptors, aiming to inhibit cancer growth and metastasis. Founded in 1994 and headquartered in Alameda, California, Exelixis plays a vital role in oncology by challenging treatment norms and broadening therapeutic options for patients worldwide.